I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
PR Newswire Asia
- Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting..
News and Video Search Results
News coverage
0 shares
1 views
You might like
WeChat media coverage
Trip.com's Weekend Super Sale upgrades to Weekly Super Sale
PR Newswire Asia
HONG KONG, May 23, 2022 /PRNewswire/ -- Trip.com's Weekend Super Sale has been a huge hit in Hong Kong since it was launched last..
Advertisement
More coverage
I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
PR Newswire Asia
SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage..
